Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $11.71.

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Wednesday, September 4th. Citigroup lifted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Royal Bank of Canada raised their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Evercore ISI raised their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th.

Insider Activity

In other news, insider Kevin Lee Freeman sold 7,500 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company's stock, valued at approximately $1,847,460.82. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the sale, the chief operating officer now owns 129,690 shares of the company's stock, valued at approximately $998,613. This trade represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,068 shares of company stock valued at $257,555. Company insiders own 2.50% of the company's stock.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC boosted its holdings in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company's stock worth $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company's stock worth $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Health Catalyst in the 1st quarter worth $8,780,000. Nepsis Inc. raised its position in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company's stock worth $17,131,000 after purchasing an additional 851,448 shares during the period. Finally, Fred Alger Management LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at $6,858,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Stock Performance

Shares of HCAT stock traded up $0.39 during mid-day trading on Monday, reaching $8.52. 555,035 shares of the company were exchanged, compared to its average volume of 561,347. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business's 50 day simple moving average is $8.13 and its 200 day simple moving average is $7.27. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst's revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.22) earnings per share. On average, analysts forecast that Health Catalyst will post -0.35 EPS for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.